Skip to main navigation Skip to search Skip to main content

Bacillus Calmette-Guérin scar reactivation (BCGitis) in Kawasaki disease: a scoping review

  • Walsall Healthcare NHS Trust

Research output: Contribution to journalReview articlepeer-review

Abstract

The aim of this study is to map and synthesise the evidence on the scattered and heterogeneous reported prevalence of Bacillus Calmette-Guérin (BCG) scar reactivation (BCGitis) in Kawasaki disease (KD), examine clinical relationships, and identify knowledge gaps for future research. A scoping review was conducted according to the PRISMA-ScR guidelines. PubMed, Scopus, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), and KoreaMed were searched for observational studies of BCG-vaccinated children with KD. We retrieved the prevalence of BCGitis and its relationship with age, sex, KD form, BCG vaccine strain, coronary artery abnormalities (CAA), and treatment response. Fifteen studies from five Asian countries (Japan, Korea, Taiwan, China, and Singapore), including 21,880 children with KD, were identified. The median reported prevalence of BCGitis was 37.5% (range, 3.5%–75.2%), driven by a few large studies. Its prevalence was 61.8% below 2 years and 9.1% over 2 years in 17,000 patients with KD. Its unweighted study-level prevalence (MU-SLP) was slightly higher in males than in females (49.8% vs. 46.1%), and in the largest number of patients with KF reported, it was associated with lower CAA rates of 11.6 vs.13.8% in the absence of BCGitis. No significant relationships were observed between KD type, vaccine strain, or treatment response. Conclusion: Owing to the inherent methodology and limitations of scoping reviews, these findings should be interpreted as a map of the current evidence rather than a quantitative conclusion. BCGitis is a common manifestation of KD in BCG-vaccinated children and may have diagnostic value, particularly in younger children, in whom diagnosis may be difficult. Although it also seems to have prognostic value regarding the development of CAA, we urge caution because confounding cannot be ruled out. However, the current evidence lacks robustness due to the heterogeneity and design limitations of the studies. Future research addressing these limitations is required. (Table presented.) Trial registration: Hassib Narchi and Alyson Skinner. Bacillus Calmette-Guérin scar reactivation (BCGitis) in Kawasaki disease. A Scoping Review. MedRxiv [preprint]. October 5, 2025. doi: https://doi.org/10.1101/2025.10.03.25337219,

Original languageEnglish
Article number289
JournalEuropean Journal of Pediatrics
Volume185
Issue number5
DOIs
StatePublished - May 2026

Keywords

  • Bacillus Calmette-Guérin
  • Children
  • Coronary
  • Diagnostic
  • Prognosis
  • Vaccination

Fingerprint

Dive into the research topics of 'Bacillus Calmette-Guérin scar reactivation (BCGitis) in Kawasaki disease: a scoping review'. Together they form a unique fingerprint.

Cite this